NYXH Stock — Nyxoah

Nyxoah (NYXH)

Updated October 16, 2026.

NYXH is a Stock. Total return is -95.4% over the past 5.5 years, 192.2 points behind SPY at 96.8%.

Nyxoah SA is a medical technology company that develops and commercializes treatments for obstructive sleep apnea, with its lead product being the Genio system, a hypoglossal neurostimulation therapy. The company does not currently have an established distribution schedule. This security may appeal to investors seeking exposure to the medical device sector and companies focused on sleep disorder treatments.

NYXH performance versus SPY

Price and return data through 2026-10-16.

Total return is -95.4% over the past 5.5 years, 192.2 points behind SPY at 96.8%. Over the past year its total return — price change plus distributions reinvested — is -81.2%. Its deepest 1-year drawdown was 81.2%.

NYXH key facts

Asset type

Stock

Asset class

Equity

Inception date

04/28/2021

Distribution frequency

None

Last close

$1.11 (as of 2026-10-16)

Market cap

$113,042,641

Average volume

210220.0

Beta

1.001

Payout ratio

0.0%

EPS

$-2.56

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

NYXH risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 81.2%.

Who may consider NYXH — and who may not

It is a weaker fit for investors who need monthly cash flow (NYXH does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on NYXH

• All tickers starting with N

Tagged: Healthcare.

Frequently asked questions